All Sites Now Recruiting for GSK Exon 51 Skipping Trial: The purpose of this study is to determine if GSK2402968 is effective in the treatment of ambulant boys with DMD resulting from a mutation thought to be corrected by exon 51 skipping. Two doses of GSK2402968 and placebo will be used in this study. This study is sponsored by GlaxoSmithKline (GSK).
This study will be conducted in the United States only and is now recruiting at 14 different sites in the following cities: Sacramento CA; Stanford, CA; Pensacola, FL; Iowa City, IA; Kansas City, KS; Baltimore, MD; Minneapolis, MN; St. Louis, MO; New York City, NY; Durham, NC; Cincinnati, OH; Columbus, OH; Portland, OR and Dallas TX.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment